38 reports

Social Anxiety Disorder (SAD Social Phobia) Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Social Anxiety Disorder (SAD Social Phobia) Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Social Anxiety Disorder (SAD Social Phobia) Clinical...

  • Anxiety Disorder
  • Clinical Trial
  • World
  • Europe
  • G7
  • APAC
  • Diagnostic Imaging Density

Abstract: - Global Anxiety Disorder Treatment Market to Reach $7.2 Billion by 2027 - Amid the COVID-19 crisis, the global market for Anxiety Disorder Treatment estimated at US$6.6 Billion in the year 2020, is projected to reach a revised size of US$7.2 Billion by 2027, growing at a CAGR of 1.3% over the analysis period...

  • Anxiety Disorder
  • World
  • China
  • United States

Abstract: - Global Antidepressants Market to Reach $15.1 Billion by 2027 - Amid the COVID-19 crisis, the global market for Antidepressants estimated at US$14.2 Billion in the year 2020, is projected to reach a revised size of US$15.1 Billion by 2027, growing at a CAGR of 1% over the analysis period 2020-2027. Major...

  • Antidepressant
  • Anxiety Disorder
  • World
  • China
  • United States

Anxiety Disorders (Central Nervous System) - Drugs in Development, 2021 Summary Anxiety Disorders (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Anxiety Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under...

  • Neurology
  • Anxiety Disorder
  • World

Generalized Anxiety Disorder (GAD) (Central Nervous System) - Drugs in Development, 2021 Summary Generalized Anxiety Disorder (GAD) (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Generalized Anxiety Disorder (GAD) pipeline landscape. The report provides comprehensive...

  • Anxiety Disorder
  • Neurology
  • World

Social Anxiety Disorder (SAD/Social Phobia) (Central Nervous System) - Drugs in Development, 2021 Summary Social Anxiety Disorder (SAD/Social Phobia) (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Social Anxiety Disorder (SAD/Social Phobia) pipeline landscape. The...

  • Anxiety Disorder
  • World

Antidepressant Drugs Market by Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors, and Others), Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety...

  • Antidepressant
  • Hormone
  • Anxiety Disorder
  • World
  • APAC
  • Europe
  • Depression Prevalence

The report considers the present scenario of the global mental wellness market and its market dynamics for 2022?2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyses leading companies and several other prominent...

  • Mental Health
  • Addiction Disorder
  • Anxiety Disorder
  • World
  • APAC
  • Alcohol Excessive Use
  • Health Expenditure

Metabotropic Glutamate Receptor 5 - Pipeline Review, H2 2020 Summary Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding...

  • Mental Health
  • Psychotic Disorder
  • Pharmaceutical
  • Drug Development
  • Therapy
  • Neurological Disorder
  • Anxiety Disorder
  • World
  • Diagnostic Imaging Density
  • Illicit Drug Use

Global Psychiatry Partnering 2015 to 2022 provides the full collection of Psychiatry disease deals signed between the world’s pharmaceutical and biotechnology companies since 2015. Trends in Psychiatry partnering deals Financial deal terms for headline, upfront and royalty by stage of development Psychiatry partnering...

  • Neurological Disorder
  • Anxiety Disorder
  • Dementia
  • Sleep Aid
  • Personality Disorder
  • World

This report is 80% complete and can be delivered within three working days post order confirmation and will include the latest impact analysis of Covid-19 in 2020 and forecast. Global Behavioral Rehabilitation Market By Application (Anxiety Disorder, Mood Disorder, Substance Abuse Disorder, Personality Disorder, Attention...

  • Mental Health
  • Specialty Hospital
  • Depression
  • Anxiety Disorder
  • World
  • Depression Prevalence

Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2020 Summary According to the recently published report ’Metabotropic Glutamate Receptor 5 – Pipeline Review, H1 2020’; Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 19 molecules. Out of...

  • Psychotic Disorder
  • Drug Development
  • Therapy
  • Neurological Disorder
  • Mental Health
  • Anxiety Disorder
  • World
  • Diagnostic Imaging Density
  • Illicit Drug Use

Report Scope: The report offers an exhaustive description and evaluation of the global stress management market.It provides in-depth qualitative and quantitative insights into the report, which aligns with the goals and objectives of our intended customers. The projections are verified through intensive primary and...

  • Anxiety Disorder
  • Personality Disorder
  • World
  • Elderly Population
  • Paid Claims

Summary TheraNova LLC (TheraNova) is a medical device company.It develops practical solutions to healthcare markets. The company offers medical device design process such as electrical engineering, mechanical engineering, silicone molding, experimental test design, software engineering, quality system implementation,...

  • Clinical Trial
  • Anxiety Disorder
  • United States
  • World
  • North America
  • Medical Devices Sales

The ongoing clinical trial research report- “2019 Social Anxiety Disorders (SAD) Ongoing Clinical Trials Study” analyzes the current scenario of all active Social Anxiety Disorders (SAD) trials across the world. The report presents top level analysis of global Social Anxiety Disorders (SAD) clinical trials across countries, companies and universities....

  • Anxiety Disorder
  • Clinical Trial
  • World
  • APAC

Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs); Atypical Antipsychotics, Tricyclic Antidepressants (TCAs), Serotonin Antagonist and Reuptake Inhibitors (SARIs), Benzodiazepines; Monoamine Oxidase Inhibitors (MAOIs), Major Depressive Disorder (MDD), General Anxiety Disorder (GAD),...

  • Antidepressant
  • Anxiety Disorder
  • Hormone
  • World

The global clinical trial report- “2019 Social Anxiety Disorders (SAD) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Social Anxiety Disorders (SAD). It presents in-depth analysis of Social Anxiety Disorders (SAD) clinical trials across markets and companies. The research work is for providing complete...

  • Anxiety Disorder
  • Clinical Trial
  • World

This study covers the world outlook for anxiety disorder therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These...

  • Anxiety Disorder
  • World
  • Gross Domestic Product
  • Disposable Income

This study covers the world outlook for anxiety disorders and depression treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the...

  • Anxiety Disorder
  • Antidepressant
  • World
  • Gross Domestic Product
  • Disposable Income

Depression and Anxiety Disorders Drug Development Pipeline Review, 2018 Summary PTSD is a mental health condition that is triggered by either experiencing or witnessing a traumatic event. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event....

  • Depression
  • Anxiety Disorder
  • Drug Approval
  • Prescription Drug Sales

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2018 Summary Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 26 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes....

  • Neurological Disorder
  • Drug Development
  • Therapy
  • Mental Health
  • Pharmaceutical
  • Anxiety Disorder
  • World
  • Diagnostic Imaging Density
  • Illicit Drug Use

This study covers the world outlook for major depressive (MDD), obsessive-compulsive (OCD), generalized anxiety (GAD), and panic (PD) disorder antidepressants across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of...

  • Anxiety Disorder
  • Depression
  • Personality Disorder
  • Antidepressant
  • World
  • Gross Domestic Product
  • Disposable Income

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H1 2018 Summary Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 25 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes....

  • Neurological Disorder
  • Drug Development
  • Therapy
  • Mental Health
  • Anxiety Disorder
  • Pharmaceutical
  • World
  • Diagnostic Imaging Density
  • Illicit Drug Use

General Anxiety Disorder ongoing clinical trials report provides comprehensive analysis and trends in global General Anxiety Disorder disease clinical trials. The research work analyzes the ongoing General Anxiety Disorder clinical trial trends across countries and companies. The report focuses on drugs and therapies being evaluated...

  • Clinical Trial
  • Anxiety Disorder
  • World

Social Anxiety Disorders (SAD) ongoing clinical trials report provides comprehensive analysis and trends in global Social Anxiety Disorders (SAD) disease clinical trials. The research work analyzes the ongoing Social Anxiety Disorders (SAD) clinical trial trends across countries and companies. The report focuses on drugs and therapies...

  • Anxiety Disorder
  • Clinical Trial
  • World

This study covers the latent demand outlook for anxiety disorder therapeutics across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,600 cities in the United States. For each city in question, the percent share the city...

  • Anxiety Disorder
  • United States
  • Disposable Income
  • Purchasing Power Parity

This study covers the latent demand outlook for anxiety disorder therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is...

  • Anxiety Disorder
  • India
  • United States
  • Disposable Income
  • Purchasing Power Parity

This study covers the latent demand outlook for anxiety disorder therapeutics across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter...

  • Anxiety Disorder
  • China
  • Disposable Income
  • Purchasing Power Parity

This study covers the latent demand outlook for anxiety disorders and depression treatments across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,600 cities in the United States. For each city in question, the percent...

  • Antidepressant
  • Anxiety Disorder
  • United States
  • Disposable Income
  • Purchasing Power Parity

This study covers the latent demand outlook for anxiety disorders and depression treatments across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share...

  • Antidepressant
  • Anxiety Disorder
  • India
  • United States
  • Disposable Income
  • Purchasing Power Parity